Australia's new Coalition "supports the sustainability of the PBS" as R&D spending rises

9 September 2013

The result of Australia’s election which was held on Saturday could have wider implications for the country’s pharmaceutical industry.

Liberal-National Coalition leader Tony Abbott is likely to be sworn in as Prime Minister next week after Saturday's decisive election win, replacing outgoing Labor leader Kevin Rudd. Mr Abbott's Liberal-National coalition won a commanding lower house majority, ending six years of Labor party rule.

Former Shadow Minister for Health & Ageing Peter Dutton is widely expected to take the health portfolio when Mr Abbott announces his Cabinet.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical